Researchers at the National Cancer Institute discovered that modulating a specific p53 isoform increases the number of inducible pluripotent stem cells (iPS) that can be obtained from cells that are being re-programmed to obtain pluripotent cells. It is known that the activity of p53 regulates the self-renewal and pluripotency of normal and cancer stem cells, and also affects re-programming efficiency of iPS cells. This p53 isoform-based technology provides a more natural process of increasing iPS cell production than previous methods of decreasing p53.
The National Cancer Institute, Laboratory of Human Carcinogenesis, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Retroviral and Lentiviral Vectors.
- Stem cell-based regenerative medicine
- Cancer therapeutic that targets cancer stem cells
- The retroviral and lentiviral vectors in this invention allow more selective control of p53 activities than siRNA or mutant p53 methods.
- Foreign Filed: Canada - Patent Application 2812300, Filed 15 Mar 2013
- Foreign Issued: European - Patent Number 2622065, Issued 07 Sep 2016
- Foreign Issued: Germany - Patent Number 602011030.80005, Issued 07 Sep 2016
- Foreign Issued: France - Patent Number 2622065, Issued 07 Sep 2016
- Foreign Issued: United Kingdom - Patent Number 2622065, Issued 07 Sep 2016